Izvorni znanstveni članak
https://doi.org/10.21857/yvjrdcdjgy
In search of novel uremic toxins: a proteomics-based pilot ELISA study
Ruđer Novak
; Center for Translational and Clinical Research, Department of Proteomics, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia
Lana Paulić
; School of Medicine, University of Zagreb, 10000 Zagreb, Croatia
Klara Pintarić
; School of Medicine, University of Zagreb, 10000 Zagreb, Croatia
Klaudia Babić
; School of Medicine, University of Zagreb, 10000 Zagreb, Croatia
Tin Plaftak
; School of Medicine, University of Zagreb, 10000 Zagreb, Croatia
Ivan Udiljak
; School of Medicine, University of Zagreb, 10000 Zagreb, Croatia
Grgur Salai
; Department of Pulmonology, University Hospital Dubrava, 10000 Zagreb, Croatia
Stela Hrkač
; School of Medicine, University of Zagreb, 10000 Zagreb, Croatia
Ivana Kovačević Vojtušek
; University Department of Health Studies, University of Split, 21000 Split, Croatia
Lovorka Grgurević
; Department of Anatomy, “Drago Perovic”, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia
*
* Dopisni autor.
Sažetak
Introduction: Uremic toxins are harmful metabolites that accumulate in the body of patients in parallel with the loss of renal function. Based on the results from a previous shotgun proteomics study that identified lumican, matrix remodeling associated 5 (MXRA5), neuropilin 1 (NRP1), and leucine-rich alpha-2-glycoprotein (LRG) as potential uremic toxins, we conducted a small pilot study in order to determine their expression levels in plasma and urine across the stages of chronic kidney disease (CKD).
Materials and methods: We conducted a cross-sectional study in which participants were divided into six subgroups (CKD1-5 and healthy controls). We determined the expression levels of lumican, MXRA5, NRP1 and LRG from blood plasma and expression levels of MXRA5, NRP1 and LRG from urine using enzyme-linked immunosorbent assays.
Results: This study included a total of N=40 participants, divided across 6 subgroups. We found no statistically significant differences in blood plasma expression levels between the subgroups for any of the assessed protein. However, we found that urinary concentration of NRP1 and LRG to be statistically significantly higher in the CKD stages 2-5 group as compared to the healthy + CKD1, with arithmetic mean of NRP1 being 3.2 times higher and arithmetic mean of LRG 19.4 times higher in the CKD stages 2-5 comparing to healthy + CKD1.
Conclusions: We did not find that any of the assessed proteins followed the expected kinetics which would be expected for uremic toxins. However, urinary LRG and NRP1 could potentially be new biomarker candidates for CKD – but further research is needed.
Ključne riječi
chronic kidney disease; uremic toxins; NRP1; LRG
Hrčak ID:
326021
URI
Datum izdavanja:
20.12.2024.
Posjeta: 0 *